Familial breast cancer targeted sequencing with ONT
A large cohort of 600 cases with familial breast cancer as classified by the Spanish Society of Medical Oncology (SEOM) Clinical Guidelines Update that were recruited during 6 years at Hospital Universitario Morales Meseguer (Murcia, Spain) were retrospectively evaluated to select 16 cases with no positive finding in NGS analysis of 20 genes implicated in this disease. These 16 cases were selected for further investigation using nanopore sequencing. This method involved the use of adaptive sampling enrichment, targeting a panel of 18 human genome regions, which contained the 20 genes (PTEN, ATM, BRCA2, PALB2, CDH1, TP53, NF1, RAD51D, BRCA1, RAD51C ,BRIP1, STK11, CHEK2, EPCAM, MSH2, MSH6, BARD1, MLH1, PMS2, NBN). In 5 samples (P1, P2, P4, P15 and P16) no selection of long reads was performed. Additionally, in 3 samples (P7, P9 and P10), both procedures were performed in two independent runs, and for the second run of P7, the DNA was previously fragmented using g-TUBE Covaris® (ref 520079) according to the protocol for 6 kb fragments.
- 19 samples
- DAC: EGAC00001003321
- Technology: MinION
Genomic Data Access Policy: This policy outlines the guidelines and procedures established by Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS) for accessing and using genomic data. It specifically addresses the data uploaded to the EGA (European Genome-phenome Archive), ensuring responsible and secure handling of the data for research and educational purposes.
1. Purpose: The purpose of this genomic data access policy is to establish guidelines and procedures for accessing and using genomic data collected and stored by Funciación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS)/IMIB. It ensures that genomic data is handled in a responsible, ethical, and secure manner, while promoting scientific research and advancements. 2. Scope: This policy applies to all individuals, including researchers, employees, and external collaborators, who want to access or use genomic data held by Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS)/IMIB and stored in EGA (European Genome-phenome Archive). 3. Data Access Requests and EGA Data Submission: a. Access to genomic data in EGA shall be granted only to authorized individuals who have a legitimate need to conduct scientific research or fulfill their professional responsibilities. b. All individuals involved in the data submission process must follow the EGA data submission guidelines and comply with any additional requirements specified by FFIS and EGA. 4. Data Use and Sharing: a. Genomic data accessed and uploaded to the EGA database must be used solely for the purposes specified in the approved Data Access Agreement (DAA) and in accordance with the EGA data sharing policies. b. Researchers and individuals involved in the data submission process shall not share, disclose, or transfer genomic data to third parties without explicit permission from the Data Access Committee (DAC). c. When publishing research findings based on the genomic data, researchers should acknowledge the data source and comply with any data sharing policies or publication guidelines set by FFIS. 5. Data Security and Confidentiality: a. Genomic data must be stored and transmitted in a secure manner, using appropriate encryption and access controls, to prevent unauthorized access, loss, or theft. b. Individuals accessing genomic data shall comply with all relevant data protection laws and regulations, maintaining strict confidentiality and privacy of the data. 6. Compliance and Monitoring: a. Compliance with this policy shall be regularly monitored by the DAC. b. Non-compliance with this policy may result in disciplinary actions, including revocation of data access privileges, as deemed appropriate.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
Other |